Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 19, 2021
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
[ Mon, Jul 19th 2021
] - WOPRAI
Fri, July 16, 2021
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
[ Fri, Jul 16th 2021
] - WOPRAI
Vikram Purohit Maintained (TBPH) at Buy with Decreased Target to $27 on, Jul 16th, 2021
Vikram Purohit of Morgan Stanley, Maintained "Theravance Biopharma, Inc." (TBPH) at Buy with Decreased Target from $28 to $27 on, Jul 16th, 2021.
Vikram has made no other calls on TBPH in the last 4 months.
There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vikram
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $36 on, Monday, June 28th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $32 on, Wednesday, May 5th, 2021
